These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy of voriconazole treatment in chronic vulvovaginal candidosis due to Candida glabrata].
    Author: Gomez-Moyano E, Cid Lama A, Fernández Ballesteros MD, Lova Navarro M, Vera Casaño A, Crespo Erchiga V.
    Journal: Rev Iberoam Micol; 2013 Jan 03; 30(1):61-3. PubMed ID: 22885618.
    Abstract:
    BACKGROUND: Vulvovaginal candidosis is a common infection in young women, and it is associated with high morbidity and high health costs. AIMS: Vulvovaginal candidosis caused by Candida glabrata is a therapeutic challenge due to the acquired resistance of many strains of this species to azole antifungals. METHODS: We present two cases of vaginal candidosis complicated by fluconazole-resistant Candida glabrata, and treated with voriconazole. RESULTS: Both patients improved after administration of voriconazole, 400 mg/12 h the first day and then 200 mg every 12 h for 14 days. Their symptoms disappeared and cultures became negative. CONCLUSIONS: These results suggest voriconazole can be used as a therapeutic alternative for this type of candidosis which, although not life threatening, is associated with a high morbidity.
    [Abstract] [Full Text] [Related] [New Search]